Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America

Ray Manneh, Ricardo Brugés, Jose Jaime Correa, Julián Rojas, Daniel Rojas, Nicolás Villareal

Research output: Contribution to journalReview articlepeer-review

Abstract

Most prostate cancer patients who undergo androgen-deprivation therapy or orchiectomy will eventually develop castration-resistant prostate cancer (CRPC), often preceded by a nonmetastatic CRPC state known as M0CRPC. The recent development of second-generation antiandrogens provides clinicians with efficacious and safe treatments for M0CRPC. However, the complexity of these patients, who typically have to deal with underlying comorbidities and polypharmacy, often challenges therapeutic decisions in this setting. The recent development of novel imaging techniques also provides clinicians with tools for detecting metastases with high sensitivity and specificity. However, the lack of evidence on the early detection of metastases and the corresponding impact on therapeutic decisions makes these techniques a double-edged sword that must be managed appropriately. Here, we present the expert view of the rapidly evolving concept of M0CRPC and provide recommendations for the identification of these patients, the appropriate use of the emerging imaging modalities, and patients' management, particularly considering their clinical complexity and the recent development of next-generation antiandrogens.

Original languageEnglish
Article number3334333
JournalProstate Cancer
Volume2021
DOIs
StatePublished - 2021

Fingerprint

Dive into the research topics of 'Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America'. Together they form a unique fingerprint.

Cite this